Change in expression of survivin caused by using oxaliplatin in HCT116 colon cancer cells

Journal of the Korean Society of Coloproctology

Volumn 26, Issue 4, 2010, Pages 246-253

  Sohn, Won Jun ^a   Lee, Jung Won ^a   Park, Dong Guk ^a  

^a Dankook University   (South Korea)

Author keywords

Colorectal cancer; Microtubule; Mitosis; Oxaliplatin; Survivin

Indexed keywords

MESSENGER RNA; OXALIPLATIN; SURVIVIN; SURVIVIN 2B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE PHASE; CELLULAR DISTRIBUTION; COLON CANCER; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; IC 50; MICROTUBULE; MITOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 77957297169     PISSN: 20937822     EISSN: 20937830     Source Type: Journal    
DOI: 10.3393/jksc.2010.26.4.246     Document Type: Article

References (29)

1. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001;93:583-96.
2. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE, et al. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 2002;9:1334-42.
3. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002;115:575-85.
4. Kemeny N, Israel K, Niedzwiecki D, Chapman D, Botet J, Minsky B, et al. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J Clin Oncol 1990;8:313-8. (Pubitemid 20056563)
5. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Pauli K, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institutes Anticancer Drug Screen panel. Biochem Pharmacol 1996;52:1855-65. (Pubitemid 26419675)
6. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002;1:227-35.
7. Fujie Y, Yamamoto H, Ngan CY, Takagi A, Hayashi T, Suzuki R, et al. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 2005;35:453-63. (Pubitemid 41309198)
8. Meng H, Lu C, Mabuchi H, Tanigawa N. Prognostic significance and different properties of survivin splicing variants in gastric cancer. Cancer Lett 2004;216:147-55. (Pubitemid 39463318)
9. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3: 917-21. (Pubitemid 27353455)
10. Duckett CS, Nava VE, Gedrich RW, Clem RJ, Van Dongen JL, Gilfillan MC, et al. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J 1996;15:2685-94.
11. Chen Z, Naito M, Hori S, Mashima T, Yamori T, Tsuruo T. A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem Biophys Res Commun 1999;264:847-54.
12. Chantalat L, Skoufias DA, Kleman JP, Jung B, Dideberg O, Margolis RL. Crystal structure of human survivin reveals a bow tieshaped dimer with two unusual alpha-helical extensions. Mol Cell 2000;6:183-9.
13. Altieri DC. New wirings in the survivin networks. Oncogene 2008;27:6276-84.
14. Gianani R, Jarboe E, Orlicky D, Frost M, Bobak J, Lehner R, et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 2001;32:119-25. (Pubitemid 32150638)
15. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999;341:452-3.
16. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324-8.
17. Wakana Y, Kasuya K, Katayanagi S, Tsuchida A, Aoki T, Koyanagi Y, et al. Effect of survivin on cell proliferation and apoptosis in gastric cancer. Oncol Rep 2002;9:1213-8.
18. Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M, et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 2001;163: 109-16.
19. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000;31:1080-5.
20. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-4.
21. Yamamoto T, Manome Y, Nakamura M, Tanigawa N. Down regulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur J Cancer 2002;38:2316-24.
22. Chen WC, Liu Q, Fu JX, Kang SY. Expression of survivin and its significance in colorectal cancer. World J Gastroenterol 2004; 10: 2886-9.
23. Knutsen A, Adell G, Sun XF. Survivin expression is an independent prognostic factor in rectal cancer patients with and without preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2004;60: 149-55.
24. Capalbo G, Rödel C, Stauber RH, Knauer SK, Bache M, Kappler M, et al. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. Strahlenther Onkol 2007;183:593-9.
25. Baek MJ, Lee EM, Kim CJ, Park NK, Shin EJ, Jang YS, et al. Expression of Survivin and Its Correlation with Prognosis in Colorectal Cancer. J Korean Soc Coloproctol 2006;22:125-31.
26. Islam A, Kageyama H, Hashizume K, Kaneko Y, Nakagawara A. Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-beta/2B. Med Pediatr Oncol 2000;35:550-3.
27. O'Driscoll L, Linehan R, M Kennedy S, Cronin D, Purcell R, Glynn S, et al. Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer. Cancer Lett 2003;201:225-36.
28. Suga K, Yamamoto T, Yamada Y, Miyatake SI, Nakagawa T, Tanigawa N. Correlation between transcriptional expression of survivin isoforma and clinicopathological findings in human colorectal carcinomas. Oncol Rep 2005;13:891-7.
29. He XF, Wen DG, Hou JQ, He J, Cen JN. Expression of survivin and the splice variants survivin-2B and survivin-ΔEx3 in bladder cancer and their clinical significance. Ai Zheng 2009;28:1209-13.